Novartis holds full control of the Kesimpta market

Novartis AG led global Kesimpta sales in 2024 with a 100% share, according to The Business Research Company’s latest market report. The finding underscores how concentrated the relapsing multiple sclerosis drug market is as self-administered B-cell therapy gains traction.

Why it matters: - Kesimpta’s market is a one-company market, with Novartis AG controlling all reported global sales in 2024. - That concentration gives Novartis outsized influence over access, clinical positioning, and competitive momentum in relapsing multiple sclerosis care. - The market’s shift toward self-administered targeted B-cell therapy reflects broader demand for convenience, adherence, and long-term disease management.

What happened: - The Business Research Company published its Kesimpta Global Market Report 2026, covering market size, trends, and a 2026-2035 forecast. - Novartis AG led global sales in 2024 with a 100% market share. - The report identifies Novartis AG as the only major company operating in the Kesimpta market. - The company’s neuroscience portfolio is positioned around targeted therapy for relapsing multiple sclerosis. - The report says the market is highly concentrated, with the top player accounting for 100% of total revenue in 2024.

The details: - Kesimpta market concentration is tied to biologic development complexity, regulatory approval requirements, specialized manufacturing, and extensive clinical validation. - Novartis holds its position through proprietary treatment portfolios, neurology expertise, commercial infrastructure, and continued investment in immunology and neuroscience. - The report lists major raw material suppliers including Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, Sartorius AG, Lonza Group AG, Fujifilm Diosynth Biotechnologies, AGC Biologics, Wacker Chemie AG, Repligen Corporation, Avantor Inc., Boehringer Ingelheim BioXcellence, Samsung Biologics, WuXi Biologics, Catalent Inc., Evonik Industries AG, Asahi Kasei Corporation, Corning Incorporated, 3M Company, Mitsubishi Gas Chemical Company, and Charles River Laboratories International Inc. - Major wholesalers and distributors include Morris & Dickson Co. LLC, Anda Inc., FFF Enterprises Inc., BioCareSD, ASD Healthcare, CuraScript SD, Oncology Supply, McKesson Specialty Health, Besse Medical, Pharmaceutical Associates Inc., Accredo Health Group Inc., CVS Specialty Inc., Optum Specialty Pharmacy, Walgreens Specialty Pharmacy, CarelonRx Specialty, AllianceRx Walgreens, and Specialty Pharmacy Network Solutions. - Major end users include Johns Hopkins Hospital, Massachusetts General Hospital, NYU Langone Health, Mount Sinai Health System, Kaiser Permanente, Cedars-Sinai Medical Center, Stanford Health Care, Northwestern Memorial Hospital, University of California San Francisco Medical Center, Vanderbilt University Medical Center, Houston Methodist Hospital, Barnes-Jewish Hospital, Duke Health, Veterans Health Administration, Apollo Hospitals, Fortis Healthcare, Max Healthcare, and specialized neurology clinics. - The report says self-administered targeted B-cell therapy is reshaping the market by improving convenience and supporting adherence. - Novartis released six-year efficacy data in April 2024 from the ALITHIOS open-label extension study for Kesimpta, showing sustained clinical benefits in recently diagnosed, treatment-naïve people with relapsing multiple sclerosis. - The therapy’s self-administered delivery, targeted B-cell depletion mechanism, and long-term efficacy profile are presented as drivers of improved accessibility, lower relapse activity, and earlier treatment use. - The report highlights company strategies including personalized multiple sclerosis treatment, longer-term clinical evidence, patient-centric drug delivery, healthcare network expansion, and clinical research investment. - The report also says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and future trend analysis.

Between the lines: - The 100% market share reading suggests Kesimpta remains highly specialized rather than broadly contested. - That kind of market structure can slow competitive entry, but it can also make clinical evidence and distribution reach more important than price competition. - The report’s emphasis on adherence and self-administration shows how delivery format is becoming part of the product’s competitive moat.

What's next: - The market outlook through 2035 will likely center on whether Novartis can extend its clinical evidence lead and maintain access across specialty care channels. - Continued expansion of specialty pharmacy networks and neurology clinic use may shape how widely Kesimpta is adopted. - Future competition in the category will likely depend on differentiated biologic data, patient convenience, and healthcare system access rather than broad market share battles.

The bottom line: - Kesimpta’s market is not crowded. Novartis controls it outright, and the next phase of competition will be about evidence, access, and patient convenience rather than volume share.